Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 76Breast 11Thoracic 6Genitourinary 5Gastrointestinal 5Sarcoma 4Head & Neck 3Other solid neoplasm 2Dermatologic 2NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 8Gastro-enteropancreatic neuroendocrine tumor 7Sarcoma 6Carcinoid Tumor 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Paraganglioma 5Neoplasms 5Prostatic Neoplasms 4Pheochromocytoma 4Neoplasm Metastasis 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Thyroid Neoplasms 3Neuroblastoma 3Carcinoma, Renal Cell 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Medulloblastoma 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × NET × Clear all
NCT05199272 2024-11-15

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

23andMe, Inc.

Phase 1/2 Active not recruiting
141 enrolled
EndocrineGenitourinaryGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡